EUVIMEDEUVIMED entdecken
Crossref

Repurposing an epithelial sodium channel inhibitor as a therapy for murine and human skin inflammation

Mårten C G Winge iD, Mazen Nasrallah, Leandra V Jackrazi iD, Konnie Q Guo iD, Jessica M Fuhriman iD, Rebecca Szafran, Muthukumar Ramanathan iD, Irina Gurevich iD, Ngon T Nguyen, Zurab Siprashvili, Mohammed Inayathullah iD, Jayakumar Rajadas und 4 weitere

Science Translational Medicine · 2024

DOI: 10.1126/scitranslmed.ade5915 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, 2024. Verfasst von Mårten C G Winge und 15 weiteren Autor:innen. Beteiligte Einrichtung: Program in Epithelial Biology, Stanford University School of Medicine, Stanford, CA 94305, USA. Hauptthemen laut MEDLINE: Keratinocytes, Amiloride, Drug Repositioning, Inflammation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 77 Literaturangaben. Gefördert von: NIGMS NIH HHS, NIAMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammatory skin disease is characterized by a pathologic interplay between skin cells and immunocytes and can result in disfiguring cutaneous lesions and systemic inflammation. Immunosuppression is commonly used to target the inflammatory component; however, these drugs are often expensive and associated with side effects. To identify previously unidentified targets, we carried out a nonbiased informatics screen to identify drug compounds with an inverse transcriptional signature to keratinocyte inflammatory signals. Using psoriasis, a prototypic inflammatory skin disease, as a model, we used pharmacologic, transcriptomic, and proteomic characterization to find that benzamil, the benzyl derivative of the US Food and Drug Administration–approved diuretic amiloride, effectively reversed keratinocyte-driven inflammatory signaling. Through three independent mouse models of skin inflammation (Rac1 G12V transgenic mice, topical imiquimod, and human skin xenografts from patients with psoriasis), we found that benzamil disrupted pathogenic interactions between the small GTPase Rac1 and its adaptor NCK1. This reduced STAT3 and NF-κB signaling and downstream cytokine production in keratinocytes. Genetic knockdown of sodium channels or pharmacological inhibition by benzamil prevented excess Rac1-NCK1 binding and limited proinflammatory signaling pathway activation in patient-derived keratinocytes without systemic immunosuppression. Both systemic and topical applications of benzamil were efficacious, suggesting that it may be a potential therapeutic avenue for treating skin inflammation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KeratinocytesAmilorideDrug RepositioningInflammationrac1 GTP-Binding ProteinSignal TransductionAnimalsHumansMiceEpithelial Sodium Channel BlockersDisease Models, AnimalAdaptor Proteins, Signal TransducingSkinPsoriasisNF-kappa BMice, TransgenicSTAT3 Transcription FactorEpithelial Sodium ChannelsImiquimod

Substanzen

Amiloriderac1 GTP-Binding ProteinEpithelial Sodium Channel BlockersbenzamilAdaptor Proteins, Signal TransducingNF-kappa BSTAT3 Transcription FactorEpithelial Sodium ChannelsImiquimod

Autor:innen und Institutionen

  • Program in Epithelial Biology, Stanford University School of Medicine, Stanford, CA 94305, USA.
  • Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
  • Unit of Dermatology, ME GHR, Karolinska University Hospital, SE-17176 Stockholm, Sweden.
  • Department of Medicine Solna, Karolinska Institutet, SE-17176 Stockholm, Sweden.
  • Advanced Drug Delivery and Regenerative Biomaterials Laboratory, Cardiovascular Institute, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA 94304, USA.
  • Dermatology Service, Veterans Affairs Medical Center, Palo Alto, CA 94304, USA.

ORCID-Profile: Mårten C G Winge, Leandra V Jackrazi, Konnie Q Guo, Jessica M Fuhriman, Muthukumar Ramanathan, Irina Gurevich, Mohammed Inayathullah, Douglas F Porter, Paul A Khavari, Atul J Butte, M Peter Marinkovich

Förderung

  • NIGMS NIH HHS
  • NIAMS NIH HHS

Zitieren

APA

Winge, M. C. G., Nasrallah, M., Jackrazi, L. V., Guo, K. Q., Fuhriman, J. M., Szafran, R., Ramanathan, M., Gurevich, I., Nguyen, N. T., Siprashvili, Z., Inayathullah, M., Rajadas, J., Porter, D. F., Khavari, P. A., Butte, A. J., & Marinkovich, M. P. (2024). Repurposing an epithelial sodium channel inhibitor as a therapy for murine and human skin inflammation. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.ade5915

Vancouver

Winge MCG, Nasrallah M, Jackrazi LV, Guo KQ, Fuhriman JM, Szafran R, et al. Repurposing an epithelial sodium channel inhibitor as a therapy for murine and human skin inflammation. Science Translational Medicine. 2024. doi:10.1126/scitranslmed.ade5915

BibTeX
@article{Winge2024,
  author = {Winge, Mårten C G and Nasrallah, Mazen and Jackrazi, Leandra V and Guo, Konnie Q and Fuhriman, Jessica M and Szafran, Rebecca and Ramanathan, Muthukumar and Gurevich, Irina and Nguyen, Ngon T and Siprashvili, Zurab and Inayathullah, Mohammed and Rajadas, Jayakumar and Porter, Douglas F and Khavari, Paul A and Butte, Atul J and Marinkovich, M Peter},
  title = {Repurposing an epithelial sodium channel inhibitor as a therapy for murine and human skin inflammation},
  journal = {Science Translational Medicine},
  year = {2024},
  doi = {10.1126/scitranslmed.ade5915}
}
Kostenlos starten →